Status:
COMPLETED
Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy
Lead Sponsor:
UCB Pharma
Conditions:
Epilepsy, Partial
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.
Eligibility Criteria
Inclusion
- Subjects with epilepsy experiencing partial seizures, whether or not secondarily generalized.
- Subjects must present between 3 and 42 partial seizures over the three months prior to protocol Visit 1.
- Use of one (1), but no more than two (2) concomitant marketed antiepileptic drugs (AEDs) at the time of trial entry.
Exclusion
- Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months.
- Presence of known pseudoseizures within the last year.
- Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors.
- Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.
Key Trial Info
Start Date :
November 24 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 12 2006
Estimated Enrollment :
251 Patients enrolled
Trial Details
Trial ID
NCT00160654
Start Date
November 24 2003
End Date
December 12 2006
Last Update
August 19 2020
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
N01036 808
Hong Kong, Hong Kong
2
N01036 842
Hong Kong, Hong Kong
3
N01036 815
Kwun Tong, Hong Kong
4
N01036 811
Kuala Lumpur, Malaysia